Chemotherapy Induced Peripheral Neuropathy Treatment Market Will Expand at 6.5% CAGR Up to 2025: QY Research, Inc.
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
View full press release